Atrial Natriuretic Factor‐Potentiating and Antihypertensive Activity of SCH 34826: An Orally Active Neutral Metalloendopeptidase Inhibitor

No abstract is available for this paper.

• Publication year

  1990

• Venue

  HYPERTENSION

• Publication date

  1990-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1161/01.HYP.15.2.152PMID 2154404
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antihypertensive Effect of a 5‐Day Infusion of Atrial Natriuretic Factor in Humans

  1989cited by this paper
• Degradation of Atrial Natriuretic Peptide: Pharmacologic Effects of Protease EC 24.11 Inhibition

  1989cited by this paper
• Enkephalinase Inhibition Increases Plasma Atrial Natriuretic Peptide Levels, Glomerular Filtration Rate, and Urinary Sodium Excretion in Rats With Reduced Renal Mass

  1989cited by this paper
• Potentiation of the Depressor Responses to Atrial Natriuretic Peptides in Conscious SHR by an Inhibitor of Neutral Endopeptidase

  1989cited by this paper
• SCH 39370, a neutral metalloendopeptidase inhibitor, potentiates biological responses to atrial natriuretic factor and lowers blood pressure in desoxycorticosterone acetate-sodium hypertensive rats.

  1989cited by this paper
• Potentiation of renal effects of atrial natriuretic factor-(99-126) by SQ 29,072.

  1989cited by this paper
• Atriopeptidase inhibitors a novel class of drugs that raises levels of endogenous atrial natriuretic factor the preclinical pharmacology of uk 69578

  1989cited by this paper
• Intrarenal localization of degradation of atrial natriuretic peptide in isolated glomeruli and cortical nephron segments.

  1988cited by this paper
• Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney.

  1988cited by this paper
• Pharmacology of SCH 34826, an orally active enkephalinase inhibitor analgesic.

  1988influential reference
• Atrial natriuretic peptides cleaved by endopeptidase are inactive in conscious spontaneously hypertensive rats.

  1988cited by this paper
• Role of endopeptidase‐24.11 in the inactivation of atrial natriuretic peptide

  1988cited by this paper
• Atrial natriuretic peptide increases resistance to venous return in rats.

  1987cited by this paper
• Atrial natriuretic factor decreases whole-body capillary absorption in rats.

  1987cited by this paper
• Effects of renal perfusion pressure on the natriuresis induced by atrial natriuretic factor.

  1987cited by this paper
• The responses of atrial natriuretic factor concentrations to acute volume changes in conscious rats.

  1987cited by this paper
• The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11.

  1987cited by this paper
• Decreased sensitivity of spontaneously hypertensive rat aortic smooth muscle to vasorelaxation by atriopeptin III.

  1987cited by this paper
• Inactivation of atrial natriuretic factor by the renal brush border.

  1987cited by this paper
• Human renal angiotensin I converting enzyme and neutral endopeptidase.

  1987cited by this paper
• Degradation of atrial natriuretic factor by kidney cortex membranes. Isolation and characterization of the primary proteolytic product.

  1987cited by this paper
• Disappearance of atrial natriuretic factor from circulation in the rat.

  1986cited by this paper
• Renal and Systemic Hemodynamic Effects of Synthetic Atrial Natriuretic Peptide in the Anesthetized Rat

  1986cited by this paper
• Atrial Natriuretic Peptide Decreases Circulatory Capacitance in Areflexic Rats

  1986cited by this paper
• Atriopeptin III kinetics and pharmacodynamics in normal and anephric rats.

  1986cited by this paper
• Decreased content in left atrium and increased plasma concentration of atrial natriuretic polypeptide in spontaneously hypertensive rats (SHR) and SHR stroke-prone.

  1986cited by this paper
• Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man.

  1986cited by this paper
• Hemodynamic Actions of a Synthetic Atrial Natriuretic Factor

  1986cited by this paper
• Differing hemodynamic responses to atrial natriuretic factor in two models of hypertension.

  1986cited by this paper
• Increased release of atrial natriuretic polypeptides in rats with DOCA-salt hypertension.

  1986influential reference
• Atrial Natriuretic Factor in Spontaneously Hypertensive Rats

  1986cited by this paper
• Atriopeptins as cardiac hormones.

  1985cited by this paper
• Changes in the content of atrial natriuretic factor with the progression of hypertension in spontaneously hypertensive rats.

  1985cited by this paper
• Effect of native and synthetic atrial natriuretic factor on cyclic GMP.

  1984cited by this paper
• Depressor and natriuretic activities of several atrial peptides.

  1984cited by this paper
• Antihypertensive Activity of SCH 31846, a Non‐Sulfhydryl Angiotensin‐Converting Enzyme Inhibitor

  1983cited by this paper
• Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides.

  1983cited by this paper
• Enkephalinase activity in rat peripheral organs.

  1981cited by this paper

• The kallikrein-kinin system as a regulator of cardiovascular and renal function.

  2011cites this paper
• Kinins and Cardiovascular Disease

  2009cites this paper
• Regional Hemodynamic Effects of Neutral Endopeptidase Inhibition and Angiotensin (AT1) Receptor Antagonism Alone or in Combination in Conscious Spontaneously Hypertensive Rats

  2006influential citation
• Potential Therapeutic Agents in Cardiovascular Disease

  2005cites this paper
• Chapter 20 – The Kallikrein-Kinin System as a Regulator of Cardiovascular and Renal Function

  2005cites this paper
• Beneficial Effects of Atrial Natriuretic Peptide

  2005cites this paper
• Vasopeptidase Inhibition: A Double-Edged Sword?

  2003cites this paper
• Neutral endopeptidase inhibition: the potential of a new therapeutic approach in cardiovascular disease evolves.

  2002cites this paper
• Atrial natriuretic peptide mimetics and vasopeptidase inhibitors.

  2001cites this paper
• Vasopeptidase inhibitors.

  2001cites this paper
• Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.

  2001cites this paper
• Effects of SA7060, a novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on deoxycorticosterone acetate-salt-induced hypertension in rats.

  2000cites this paper
• Acute and chronic neutral endopeptidase inhibition and the natriuretic response to acute volume expansion.

  1998cites this paper
• Preventive role of renal kallikrein-kinin system in the early phase of hypertension and development of new antihypertensive drugs.

  1998cites this paper
• Effects of Neutral Endopeptidase Inhibition in the Rat Remnant Kidney Model

  1998cites this paper
• ATRIAL NATRIURETIC FACTOR, its (patho)physiological significance in humans

  1998cites this paper
• Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.

  1998cites this paper
• Inhibition of kidney neutral endopeptidase after administration of the neutral endopeptidase inhibitor candoxatril: quantitation by autoradiography.

  1998cites this paper
• New or developing antihypertensive agents

  1997cites this paper
• Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11).

  1996cites this paper
• Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt.

  1996cites this paper
• Cardiorenal consequences of dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibition in transgenic rats with an extra renin gene.

  1996cites this paper
• Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship.

  1996cites this paper
• Excretory responses to renal nerve stimulation during inhibition of neutral metalloendopeptidase and angiotensin-converting enzyme in the rat.

  1996cites this paper
• Effects of angiotensin-converting enzyme and neutral endopeptidase inhibitors: influence of bradykinin.

  1996cites this paper
• Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action.

  1996cites this paper
• Pharmacology of S21402 (RB105): A Dual Inhibitor of Neutral Endopeptidase and Angiotensin Converting Enzyme

  1996cites this paper
• Endopeptidase inhibition in angiotensin-induced hypertension. Effect of SCH 39370 in sheep.

  1995cites this paper
• Experimental Hypertension and Therapeutic Progress: Vasodilation and Beyond

  1995cites this paper
• Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.

  1995cites this paper
• Prolonged inhibition of neutral endopeptidase 24.11 by sinorphan in stroke-prone spontaneously hypertensive rats.

  1995cites this paper
• Ebelactone B, an inhibitor of urinary carboxypeptidase Y-like kininase, prevents the development of deoxycorticosterone acetate-salt hypertension in rats.

  1995cites this paper
• Clinical Relevance of Atrial Natriuretic Peptide

  1995cites this paper
• Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension

  1995cites this paper
• Dual Inhibition of Angiotensin‐Converting Enzyme and Neutral Endopeptidase in Rats with Hypertension

  1995cites this paper
• The effect of heteroatom substitution on a series of phosphonate inhibitors of neutral endopeptidase 24.11

  1994cites this paper
• Mechanisms of the Natriuretic Effects of Neutral Endopeptidase Inhibition in Dahl Salt‐Sensitive and Salt‐Resistant Rats

  1994cites this paper
• Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11.

  1994cites this paper
• Calcitonin gene-related peptide is not elevated in rat plasma by heart failure or by neutral endopeptidase inhibition.

  1994cites this paper
• CGS 24128: A Long-Acting Inhibitor of Neutral Endopeptidase 3.4.24.11

  1994cites this paper
• Inhibition of either angiotensin-converting enzyme or neutral endopeptidase induces both enzymes.

  1994cites this paper
• Neutral endopeptidase (NEP) inhibition in rats with established pulmonary hypertension secondary to chronic hypoxia

  1994cites this paper
• Atrial Natriuretic Peptide and Its Potential Role in Pharmacotherapy

  1994cites this paper
• Hemodynamic and Humoral Effects of Chronic Treatment with the Neutral Endopeptidase Inhibitor SCH 42495 in Spontaneously Hypertensive Rats

  1994cites this paper
• Models used to assess renal function

  1994cites this paper
• Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats.

  1993cites this paper
• Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.

  1993cites this paper
• Atrial Natriuretic Peptide

  1993cites this paper
• Comparison of Cyclic Guanosine Monophosphate Response to Infusion of Atrial Natriuretic Peptide in Young and Elderly Subjects

  1993cites this paper
• Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

  1993cites this paper
• Disparate effects of phosphoramidon on blood pressure in SHR and DOCA-salt hypertensive rats.

  1993cites this paper
• Heterocyclic lactam derivatives as dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibitors.

  1993cites this paper
• Receptor antagonists of bradykinin: a new tool to study the cardiovascular effects of endogenous kinins.

  1993cites this paper
• Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man.

  1993cites this paper
• Concurrent neutral endopeptidase and ACE inhibition in experimental heart failure: renal and hormonal effects.

  1993cites this paper
• Zinc metallopeptidases: active site structure and design of selective and mixed inhibitors: new approaches in the search for analgesics and anti-hypertensives.

  1993cites this paper
• Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology.

  1993cites this paper
• Renal effects of neutral endopeptidase inhibition in euvolemic and hypervolemic rats.

  1993cites this paper
• Endopeptidase-24.11 and its inhibitors: potential therapeutic agents for edematous disorders and hypertension.

  1993cites this paper
• Dose‐ranging effects of candoxatril on elimination of exogenous atrial natriuretic peptide in chronic heart failure

  1993cites this paper
• Beneficial Effects of Atrial Natriuretic Peptide on Exercise‐Induced Myocardial Ischemia in Patients With Stable Effort Angina Pectoris

  1993cites this paper
• Clinical potential of endopeptidase-24.11 inhibitors in cardiovascular disease.

  1993cites this paper
• Effects of the Selective Neutral Endopeptidase Inhibitor, Retrothiorphan, on Renal Function and Blood Pressure in Conscious Normotensive Wistar and Hypertensive DOCA-Salt Rats

  1992cites this paper
• EFFECT OF NEUTRAL ENDOPEPTIDASE INHIBITOR IN RATS WITH CONGESTIVE HEART FAILURE

  1992cites this paper
• [Identification and characterization of neutral endopeptidase in endothelial cells of arterial or venous origin].

  1992cites this paper
• Neurohormonal Inhibition and Hemodynamic Unloading During Prolonged Inhibition of ANF Degradation in Patients With Severe Chronic Heart Failure

  1992cites this paper
• Acute Inhibition of Endopeptidase 24.11 in Essential Hypertension: SCH 34826 Enhances Atrial Natriuretic Peptide and Natriuresis Without Lowering Blood Pressure

  1992cites this paper
• Degradation and inactivation of rat atrial natriuretic peptide 1-28 by neutral endopeptidase-24.11 in rat pulmonary membranes.

  1992cites this paper
• Identification and characterization of neutral endopeptidase in endothelial cells from venous or arterial origins.

  1992cites this paper
• Neurohormonal consequences of diuretics in different cardiovascular syndromes.

  1992cites this paper
• Atrial natriuretic peptide: synthesis, release, and metabolism.

  1992cites this paper
• Effects of SCH 34826, a neutral endopeptidase inhibitor, on hypoxic pulmonary vascular remodelling.

  1992cites this paper
• Localization and characterization of neutral metalloendopeptidase (EC 3.4.24.11), the degradative enzyme for atrial natriuretic peptide, in rat kidney using a radioiodinated neutral metalloendopeptidase inhibitor.

  1992cites this paper
• The Neutral Endopeptidase Inhibitor, SCH 34826, Reduces Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats

  1992cites this paper
• Atrial natriuretic factor: its (patho)physiological significance in humans.

  1992cites this paper
• Proximal tubular metalloprotease activity is decreased in the senescent rat kidney.

  1992cites this paper
• Basal and volume expansion-stimulated plasma atrial natriuretic peptide concentrations and hemodynamics in conscious rats: effects of SCH 39.370, an endopeptidase inhibitor, and C-ANF-(4-23), a clearance receptor ligand.

  1992cites this paper
• Phosphoramidon abolishes the increases in endothelin-1 release induced by ischemia-hypoxia in isolated perfused guinea pig lungs.

  1992cites this paper
• Therapeutic use of atrial natriuretic factor.

  1992cites this paper
• Analysis of the importance of arginine 102 in neutral endopeptidase (enkephalinase) catalysis.

  1992cites this paper
• Overview: The Atrial Peptide System as a Therapeutic Target

  1992cites this paper
• Therapeutic useofatrial natriuretic factor

  1992cites this paper
• Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension

  1992cites this paper
• Zinc Metallopeptidase Inhibitors A Novel Antihypertensive Treatment

  1991cites this paper
• Influence of C-ANF receptor and neutral endopeptidase on pharmacokinetics of ANF in rats.

  1991cites this paper
• Chronic inhibition of neutral endopeptidase reduces left ventricular hypertrophy without changing blood pressure in spontaneously hypertensive rats.

  1991cites this paper
• Atrial natriuretic factor in chronic heart failure.

  1991cites this paper
• Neutral Endopeptidase Inhibitors and Atrial Natriuretic Peptide

  1991cites this paper
• Role of the endopeptidase 24.11 in the disposition and metabolism of endogenous atrial natriuretic factor in the rabbit.

  1991cites this paper
• Design and Therapeutic Potential of Peptides

  1991cites this paper
• Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers

  1991cites this paper
• Phosphoramidon blocks the pressor activity of big endothelin[1-39] and lowers blood pressure in spontaneously hypertensive rats.

  1991cites this paper
• Heart Failure Augments the Cardiovascular and Renal Effects of Neutral Endopeptidase Inhibition in Rats

  1991cites this paper
• The neutral endopeptidase-24.11 inhibitor SCH 34826 does not change opioid binding but reduces D1 dopamine receptors in rat brain.

  1991cites this paper
• The blood pressure and renal responses to SCH 34826, a neutral metalloendopeptidase inhibitor, and C-ANF (4-23) in Doca-salt hypertensive rats.

  1991cites this paper
• Neutral metalloendopeptidase inhibitors as ANF potentiators: sites and mechanisms of action.

  1991cites this paper
• Antihypertensive Activity During Inhibition of Neutral Endopeptidase and Angiotensin Converting Enzyme

  1991cites this paper
• SCH 34826: an overview of its profile as a neutral endopeptidase inhibitor and ANF potentiator.

  1991cites this paper
• Prolonged neutral endopeptidase inhibition in heart failure.

  1991cites this paper
• Developing essential hypertension: a syndrome involving ANF deficiency?

  1991cites this paper